Literature DB >> 3337087

Efficacy of sequential annual vaccination with inactivated influenza virus vaccine.

W A Keitel1, T R Cate, R B Couch.   

Abstract

Inactivated influenza virus vaccine efficacy after annual revaccination has been reported to be less than that after first vaccination in boarding school children. We prospectively examined the immunogenicity and efficacy of this vaccine in healthy 30- to 60-year-old volunteers in Houston, Texas, over two epidemic seasons (1983-1985) encompassing outbreaks due to influenza A (H3N2 and H1N1) and influenza B viruses. A placebo group that had never (or not in recent years) received inactivated influenza virus vaccine, a group that received the vaccine for the first time (first vac), and a group given two or more recent vaccinations (multivac) were evaluated in a double-blind fashion each year. Vaccination induced higher frequencies of rise in serum antibody titer to vaccine components in first vac than in multivac volunteers, but mean postvaccination titers were similar. Clinical and virologic evaluations of illnesses during both epidemics and of influenza infections diagnosed serologically over the epidemic seasons revealed no overall reduction in illness from that in the placebo group for either vaccine group; modest reductions in influenza infection-related illness that were significant only for the multivac group against A/H3N2-related illness (55%; p less than 0.04); reduction in moderate-to-severe lower respiratory and/or systemic illness due to influenza for multivac (73%, p less than 0.025) but not first vac (15%, p greater than 0.10) volunteers during the A/H3N2 epidemic; reduction in influenza virus shedding in the multivac (54%, p less than 0.05) but not the first vac (16%, p greater than 0.10) group when compared with the placebo group for both years; and overall 63-81% reductions in documented infections with each influenza virus for both vaccine groups with the exception of A/H1N1 for the first vac group (24%, p greater than 0.10) and type B for the multivac group (58%, p = 0.067). Vaccine efficacy was only modest in these studies, but in contrast to the earlier report in boarding school children, efficacy appeared to be somewhat greater after repeated annual vaccination than after first administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3337087     DOI: 10.1093/oxfordjournals.aje.a114809

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  29 in total

1.  Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Ana Marie Landin; Mitch Phillips; Suzanne C Lechner; John G Ryan; Bonnie B Blomberg
Journal:  Vaccine       Date:  2010-10-23       Impact factor: 3.641

2.  Immunization of elderly volunteers with the 1988-89 inactivated whole influenza vaccine: assessment of antibody responses by haemagglutination inhibition and single radial haemolysis tests.

Authors:  A M Iorio; T Zei; M Neri; L Campitelli; M R Castrucci; I Donatelli
Journal:  Eur J Epidemiol       Date:  1992-07       Impact factor: 8.082

Review 3.  Age effects on B cells and humoral immunity in humans.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Ana Marie Landin; Bonnie B Blomberg
Journal:  Ageing Res Rev       Date:  2010-08-20       Impact factor: 10.895

Review 4.  Aging, cytomegalovirus (CMV) and influenza vaccine responses.

Authors:  Daniela Frasca; Bonnie B Blomberg
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

5.  Quantifying influenza vaccine efficacy and antigenic distance.

Authors:  Vishal Gupta; David J Earl; Michael W Deem
Journal:  Vaccine       Date:  2006-01-19       Impact factor: 3.641

Review 6.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 7.  Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review.

Authors:  Barbara Camilloni; Michela Basileo; Stefano Valente; Emilia Nunzi; Anna Maria Iorio
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 8.  Influenza vaccine responses in older adults.

Authors:  Janet E McElhaney
Journal:  Ageing Res Rev       Date:  2010-11-03       Impact factor: 10.895

9.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

10.  Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines.

Authors:  Janet E McElhaney
Journal:  Aging health       Date:  2008-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.